Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.
1 report, 1 independent
Updated Aug 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cantor Fitzgerald increased its price target on Eli Lilly and Company stock.
Who's involved
What this event is mainly aboutKeep exploring
Part of
Analyst coverage is influencing stock price targets for companies including Bank of America, Eli Lilly and Company, Leerink partners, and Cantor Fitzgerald.Also in this story
- Market developments on July 25, 2026, involving Eli Lilly and Company, Cantor Fitzgerald, and filings with the SEC.
- Bank of America and Citigroup issued buy ratings and raised price targets on July 18, 2026.
- Copeland Capital Management reduced its stake in Eli Lilly and Company shares.
- Berenberg Bank and Leerink Partners raised price targets for Eli Lilly and Company on July 8, 2026.
The entities involved
-
Cantor Fitzgerald
American financial services company
-
Eli Lilly and Company
American pharmaceutical company
Related events
- Truist Financial and Leerink Partners raised price objectives for Eli Lilly and Company stock.
- Berenberg Bank raised a price target and gave a 'hold' rating on Eli Lilly and Company, alongside filing required reports with the SEC.
- Cantor Fitzgerald raised its price target and rating for Supernus Pharmaceuticals, Inc. on September 2, 2026, and the company filed a disclosure with the SEC.
- Cantor Fitzgerald raised its price target on Salesforce on September 1, 2026.
- Analyst provides a high price target for Viking Therapeutics stock.